Clinical trials show average weight loss of 15 to 17 percent of body weight over 68 weeks
Tan, [email protected] This article was submitted to Obesity, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection
Moreover, this guide addresses a spectrum of concerns, from pharmacological properties of semaglutide and its clinical applications to practical advice for nursing mothers
A: The safety of semaglutide during pregnancy is not fully known
Long-term data on sustained weight loss maintenance with continued GLP-1 receptor agonist therapy in post-bariatric populations remains limited, highlighting the need for ongoing research and extended follow-up studies
